Priority maps are more explicit.
WHO's 2024 bacterial priority list and CDC tracking make threat ranking more inspectable.
Infectious DiseaseAMRFungal resistanceCountermeasures
Infectious Disease
As of June 2026, infectious disease is defined by uneven threat visibility: bacterial priority lists are clearer, Candida auris keeps expanding, antifungal resistance is under-tooled, and precision countermeasures depend on faster diagnostics, host-state routing, and development pathways that fit small resistant populations.
Domain research lens
This page tracks pathogen-drug pairs, resistance rise, diagnostic timing, host vulnerability, surveillance gaps, and the development paths that can work when resistant populations are small and urgent.
June 2026 field state
A field where threat visibility is improving faster than the treatment pipeline.
The strongest work combines surveillance, rapid diagnostics, drug-development flexibility, fungal biology, and host vulnerability mapping to decide where scarce countermeasure effort should go.
Resistance, pathogen threat ranking, fungal disease, host vulnerability, diagnostics, antimicrobial precision, surveillance gaps, and countermeasure design.
The domain thesis: infectious-disease diligence is not a list of pathogens. It is a routing problem across pathogen, resistance mechanism, patient context, diagnostic speed, and feasible development path.
Fungal surveillance is exposing the under-tooled threat.
CDC C. auris case tracking makes clinical expansion and resistance monitoring more visible.
The pipeline is mismatched to the threat.
Small resistant populations, diagnostic delay, weak economics, and fungal biology make conventional development fragile.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
WHO's updated bacterial priority list reframed AMR targeting.
WHO's 2024 BPPL covers 24 pathogens across 15 families, including Gram-negative bacteria resistant to last-resort drugs and other high-burden resistant pathogens.
Why it matters
Pipeline and diagnostic investment should follow burden, resistance trends, transmissibility, and treatability rather than generic AMR concern.
Decision implication
Changes which pathogen-drug pairs deserve build, partner, or monitor status.
C. auris remains a rising urgent fungal threat.
CDC reported 6,304 new U.S. clinical C. auris cases in 2024 and notes cases have increased each year since the first U.S. case was reported in 2016.
Why it matters
Fungal threat value depends on surveillance, identification, infection control, susceptibility testing, and antifungal-scarcity logic.
Decision implication
Changes whether antifungal programs need resistance-specific, broad-spectrum, or diagnostic-linked strategies.
FDA finalized flexible guidance for serious resistant bacterial disease.
FDA guidance assists development of antibacterial therapies for serious bacterial diseases in patients with limited or lacking effective alternatives.
Why it matters
Precision antibiotics may need narrower populations, flexible evidence, and pathogen-focused trial logic.
Decision implication
Changes trial design and commercial diligence for pathogen-focused countermeasures.
Fungal resistance work is exposing new target logic.
Recent C. auris resistance literature points to mechanisms and vulnerabilities that may help corner resistance rather than simply shifting susceptibility.
Why it matters
The antifungal field needs mechanisms that reduce escape pressure, not another marginal activity claim.
Decision implication
Changes whether a program is monitored as mechanistic leverage or avoided as undifferentiated antifungal activity.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
AMR prioritization
WHO priority pathogens as a development map
The 2024 BPPL gives antibiotic R&D a sharper target set, especially resistant Gram-negative organisms, drug-resistant tuberculosis, and other high-burden pathogens.
Fungal threatCandida auris surveillance and susceptibility testing
CDC tracking and AR Lab Network data make C. auris expansion and resistance visible enough to force diagnostic, infection-control, and antifungal-development decisions.
Clinical developmentLimited-population antibacterial pathways
FDA's unmet-need guidance keeps narrow resistant populations on the table, but trial feasibility and interpretable endpoints remain the commercial bottleneck.
Resistance mechanismsFungal resistance biology beyond susceptibility panels
C. auris epigenetic and metabolic vulnerability work is testing whether programs can corner resistance rather than add another marginal antifungal activity claim.
Host stateSepsis, immunosuppression, microbiome, and tissue context
Precision countermeasures increasingly depend on whether the patient's host state makes pathogen targeting sufficient or requires immune, microbiome, or source-control logic.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
Pathogen priority
Is the target a high-burden, high-resistance, treatability-limited threat?
Diagnostic timing
Can the test route therapy before empiric treatment has already decided outcome?
Resistance cornering
Does the mechanism reduce escape or merely shift resistance pressure?
Population feasibility
Can a trial enroll the right resistant population with interpretable endpoints?
Host-state fit
Does the intervention need immune rescue, microbiome routing, or source control?
Access economics
Can the product survive low-volume stewardship and procurement constraints?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
Invasive Fungal Disease & Antifungal Resistance
Maps fungal threat expansion against diagnostic timing, drug scarcity, resistance, toxicity, and host-risk stratification.
Why it belongs here
Which antifungal or diagnostic programs address the binding scarcity layer, and what evidence would change countermeasure priority?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Precision AMR Countermeasures
Uses mutational supply, diagnostic timing, pathogen burden, and combination logic to assess durability against resistance escape.
Why it belongs here
Which AMR countermeasures reduce escape paths enough to justify development, deployment, or monitoring priority?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Epigenome Editing & Tunable Permanence
Classifies whether mitotic dilution, active erasure, or reactivation pressure will dominate before buyers commit to delivery, indication, or permanence strategy.
Why it belongs here
Which epigenome-editing programs have a defensible durability strategy, and what decay force would erase the imposed mark before benefit is proven?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
Surveillance
CDC AMR threat estimates and electronic surveillance updates
More current estimates would change which pathogen-drug pairs deserve build, partner, monitor, or avoid decisions.
C. aurisEchinocandin resistance and screening expansion
Rising resistance to first-line fungal therapy would re-rank antifungal and diagnostic priorities.
Development pathwayFDA LPAD and unmet-need antibacterial precedents
New approvals or complete response letters in narrow resistant populations would reset evidence expectations.
Host-pathogen routingMaps that predict severe infection or treatment failure
The highest-value precision programs may be those that pair pathogen ID with host vulnerability and source-control decisions.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
2024-2026 / AMR ranking
Priority lists are useful only if they route development choices.
The domain page now treats pathogen ranking, treatability, and trial feasibility as linked gates.
2026 / C. auris Fungal resistance remains under-tooled relative to visibility.Surveillance is improving faster than the antifungal pipeline, which makes diagnostics and infection control part of the innovation map.
2025 / FDA guidance Narrow countermeasures need narrow-population evidence logic.Regulatory flexibility helps only if the diagnostic and enrollment strategy can find the right patients in time.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.